• Roche to present new data highlighting comprehensive approach to cancer care at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

    • May 13, 2019
    • Posted By : admin
    • 0 Comment
    •   98 views

    Roche today announced that new data from clinical trials of 17 approved and investigational medicines across 27 cancer types, including hard-to-treat and rare tumours, will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, United States, from 31 May– 4 June, 2019. A total of 155 abstracts that include a Roche medicine will be presented at this year’s meeting.

    “At this year’s ASCO meeting, we are excited to present new data with targeted therapies, immunotherapy and pipeline combinations across a broad range of diseases including blood, breast and lung cancers, as well as paediatric tumours treated with our personalised cancer medicine, entrectinib,” said Sandra Horning, MD, chief medical officer and head of Global Product Development. “Through pioneering science, strategic partnerships and data and analytics, we’re striving to develop transformative medicines that can help improve outcomes for each individual patient.”

    Further information on Roche’s contribution to the ASCO 2019 scientific programme, as well as the latest innovations and developments in Roche’s approach to accelerating progress in cancer care, will be featured during the Roche Media Briefing from 09:00 – 10:30 CDT on Friday 31 May at the Chicago Marriott Downtown Magnificent Mile, Chicago, IL, US. This event, independently organised by Roche, is open to journalists from outside the United States who have registered as media with the ASCO 2019 Annual Meeting.

  98 views

You Might Also Like

No comments found

LEAVE COMMENT

Archive

Offers
error: Content is protected !!